DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Compro (Prochlorperazine Rectal) - Summary

 
 



WARNING

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Compro® Prochlorperazine Suppositories USP is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).

 

COMPRO SUMMARY

Prochlorperazine is a clear, pale yellow, viscous liquid. It is sensitive to light, very slightly soluble in water, freely soluble in alcohol, in chloroform, and in ether. Each suppository, for rectal administration, contains 25 mg of prochlorperazine; with glycerin, glyceryl monopalmitate, glyceryl monostearate, hydrogenated coconut oil fatty acids and hydrogenated palm kernel oil fatty acids.

Prochlorperazine 25mg suppositories are indicated in the control of severe nausea and vomiting in adults.


See all Compro indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Compro (Prochlorperazine Rectal)

Arthritis Tx Self-Monitoring Can Cut Healthcare Use (CME/CE)
Source: MedPage Today Rheumatology [2015.08.27]
(MedPage Today) -- Patient safety and disease control were not compromised

miR-7 suppresses stomach cancer
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2015.08.11]
A study in The Journal of Cell Biology reveals that the microRNA miR-7 suppresses gastric (stomach) cancer by inhibiting a key signaling pathway, and that this protective mechanism is compromised by...

The uneasy, unbreakable link of money, medicine
Source: Pharma Industry / Biotech Industry News From Medical News Today [2015.08.04]
Even after centuries of earnest oaths and laws, the debate about whether money compromises medicine remains unresolved, observes Dr. Eli Adashi in a new paper in the AMA Journal of Ethics.

Data shows disconnect between healthcare professionals and patient perceptions of impact of chemotherapy and radiotherapy-induced nausea and vomiting
Source: Nursing / Midwifery News From Medical News Today [2015.06.30]
Norgine B.V. has presented new data highlighting a perceptual gap between healthcare professionals and patients in terms of the incidence and impact on patients' daily life of chemotherapy and...

Nausea and Vomiting
Source: MedicineNet Angina Specialty [2014.07.09]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 7/9/2014 12:00:00 AM

more news >>

Published Studies Related to Compro (Prochlorperazine Rectal)

Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache. [2011.04.01]
The indomethacin/prochlorperazine/caffeine fixed combination (Difmetre(R)) combines the NSAID indomethacin with the phenothiazine antiemetic prochlorperazine and caffeine. It is currently available as two oral (effervescent tablet and coated tablet) and two rectal (suppository and low-dose suppository) formulations...

more studies >>

Clinical Trials Related to Compro (Prochlorperazine Rectal)

Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine [Terminated]
The objective of this randomized, double blind study is to demonstrate that one dose oral "excedrin migraine" (acetaminophen, aspirin and caffeine) is not inferior when compared to one dose of intravenous prochlorperazine for the treatment of acute migraine headaches in the emergency department.

Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine [Recruiting]
Opioids are commonly used to treat migraine in North American Emergency Departments. We are comparing efficacy and adverse events of hydromorphone, an opioid, to that of prochlorperazine, a dopamine antagonist with known efficacy in migraine. Prochlorperazine will be combined with diphenhydramine to prevent adverse events.

Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department [Completed]
ED patients with acute migraine will be randomized to either prochlorperazine and Bendaryl OR imitrex. VAS for pain will be monitored, along with side effects. Primary outcome measure is improvement in pain scales between the groups.

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department [Completed]
This study will compare the effect of prochlorperazine and ondansetron for the treatment of nausea and vomiting in the emergency department.

Bioavailability of Prochlorperazine Suppositories, 25 mg [Completed]
The purpose of this study is to compare prochlorperazine plasma concentrations produced after administration of the test formulation with those produced after administration of a marketed reference product.

more trials >>


Page last updated: 2015-08-27

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015